#SFHS2608718VNotice Regarding Prices of Pharmaceutical Specialties Published Under Articles L. 162-16-5 and L. 162-16-6 of the Social Security Code
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This notice sets the sale prices for a specific pharmaceutical product at hospitals in France. It details the price without taxes for the product Amphotericin B supplied by Medipha Sante. Hospitals and healthcare providers should adjust their budgets and purchasing plans accordingly.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Establishes the sale price of Amphotericin B for hospitals
- Specifies tax-free pricing details
- Aligns with current health agreements
Obligations
What this law requires
Healthcare establishments must purchase Amphotericin B Liposomal 50mg (UCD code 34008900518733) supplied by Medipha Sante at the official sale price of €71.493 (excluding taxes) per unit
Healthcare establishments must adjust their pharmaceutical budgets to reflect the established sale price of €71.493 HT per unit for Amphotericin B Liposomal 50mg
Healthcare establishments must apply the responsibility rate (tarif de responsabilité) of €71.493 HT per unit for Amphotericin B Liposomal 50mg for reimbursement calculations
Medipha Sante must not sell Amphotericin B Liposomal 50mg to healthcare establishments above the maximum sale price limit of €71.493 HT per unit
Healthcare establishments must update their pharmaceutical purchasing plans to incorporate the price-controlled sale of Amphotericin B Liposomal 50mg at €71.493 HT per unit